| UHC Surest Medical and Drug | Ocrevus® (Ocrelizumab) and Ocrevus Zunovo® (Ocrelizumab and Hyaluronidase-Ocsq) – Commercial Medical Benefit Drug Policy | 2026-01-01 |
| UHC Surest Medical and Drug | Orthognathic (Jaw) Surgery – Commercial and Individual Exchange Medical Policy | 2026-01-01 |
| UHC Surest Medical and Drug | Panniculectomy Surgery – Commercial and Individual Exchange Medical Policy | 2026-01-01 |
| UHC Surest Medical and Drug | Percutaneous Neuroablation for Pancreatic Cancer Pain, Severe Cancer Pain, and Trigeminal Neuralgia – Commercial and Individual Exchange Medical Policy | 2026-01-01 |
| UHC Surest Medical and Drug | Percutaneous Patent Foramen Ovale (PFO) Closure – Commercial and Individual Exchange Medical Policy | 2026-01-01 |
| UHC Surest Medical and Drug | Pharmacogenetic Panel Testing – Commercial and Individual Exchange Medical Policy | 2026-01-01 |
| UHC Surest Medical and Drug | Plagiocephaly and Craniosynostosis Treatment – Commercial and Individual Exchange Medical Policy | 2026-01-01 |
| UHC Surest Medical and Drug | Preventive Care Services – Commercial and Individual Exchange Medical Policy | 2026-01-01 |
| UHC Surest Medical and Drug | Private Duty Nursing Services – Commercial and Individual Exchange Medical Policy | 2026-01-01 |
| UHC Surest Medical and Drug | Prolotherapy and Platelet Rich Plasma Therapies – Commercial and Individual Exchange Medical Policy | 2026-01-01 |